Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CVRX
stocks logo

CVRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
15.57M
+1.5%
-0.444
+3.32%
14.38M
+16.49%
-0.500
-5.66%
15.78M
+16.09%
-0.490
-14.04%
Estimates Revision
The market is revising Upward the revenue expectations for CVRx, Inc. (CVRX) for FY2025, with the revenue forecasts being adjusted by 0.26% over the past three months. During the same period, the stock price has changed by 19.57%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.26%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.24%
In Past 3 Month
Stock Price
Go Up
up Image
+19.57%
In Past 3 Month
Wall Street analysts forecast CVRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVRX is 12.67 USD with a low forecast of 11.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast CVRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVRX is 12.67 USD with a low forecast of 11.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.350
sliders
Low
11.00
Averages
12.67
High
14.00
Current: 9.350
sliders
Low
11.00
Averages
12.67
High
14.00
Canaccord
Buy
upgrade
$9 -> $11
2025-11-06
Reason
Canaccord
Price Target
$9 -> $11
2025-11-06
upgrade
Buy
Reason
Canaccord raised the firm's price target on CVRx to $11 from $9 and keeps a Buy rating on the shares. The firm said they reported Q3 results ahead of expectations and they believe that the company is beginning to become confident about its rep hires beginning to become productive, which it attributed to the Q3 performance but still expects the bulk of the benefit to be realized in 2026.
Cantor Fitzgerald
Ross Osborn
Overweight
maintain
$11 -> $13
2025-11-06
Reason
Cantor Fitzgerald
Ross Osborn
Price Target
$11 -> $13
2025-11-06
maintain
Overweight
Reason
Cantor Fitzgerald analyst Ross Osborn raised the firm's price target on CVRx to $13 from $11 and keeps an Overweight rating on the shares. The company reported "strong" Q3 operating results and narrowing guidance, the analyst tells investors in a research note.
JPMorgan
Neutral -> Underweight
downgrade
$15 -> $7
2025-05-09
Reason
JPMorgan
Price Target
$15 -> $7
2025-05-09
downgrade
Neutral -> Underweight
Reason
Piper Sandler
Matt O'Brien
Overweight
to
Overweight
downgrade
$20 -> $12
2025-05-09
Reason
Piper Sandler
Matt O'Brien
Price Target
$20 -> $12
2025-05-09
downgrade
Overweight
to
Overweight
Reason
Piper Sandler analyst Matt O'Brien lowered the firm's price target on CVRx to $12 from $20 and keeps an Overweight rating on the shares. The firm notes the company reported Q1 results that were in line with the pre-announcement. Management primarily attributed the miss to sales force realignment that was more substantial than initially anticipated. CVRx also lowered full year sales guidance by more than the miss in the quarter. Piper believes the new guidance is fairly set but there is no lay-up as it still anticipates some productivity improvement through year-end.
Canaccord Genuity
William Plovanic
Strong Buy
Maintains
$23 → $18
2025-04-08
Reason
Canaccord Genuity
William Plovanic
Price Target
$23 → $18
2025-04-08
Maintains
Strong Buy
Reason
Canaccord lowered the firm's price target on CVRx to $18 from $23 and keeps a Buy rating on the shares. The firm updated its model to reflect both the Q1/25 revenue miss and a lower outlook for the US given the sales force disruption. They also expect the company to continue to invest in growth and therefore operating expenses will stay similar to pre-release estimates.
Lake Street
Frank Takkinen
Strong Buy
Maintains
$19 → $14
2025-04-08
Reason
Lake Street
Frank Takkinen
Price Target
$19 → $14
2025-04-08
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for CVRx Inc (CVRX.O) is -4.92, compared to its 5-year average forward P/E of -6.10. For a more detailed relative valuation and DCF analysis to assess CVRx Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.10
Current PE
-4.92
Overvalued PE
-3.40
Undervalued PE
-8.80

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.74
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.13
Undervalued EV/EBITDA
-11.61

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
7.36
Current PS
0.00
Overvalued PS
12.18
Undervalued PS
2.53
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

CVRX News & Events

Events Timeline

(ET)
2025-11-05
16:30:55
CVRx Projects FY25 Revenue Between $55.6M and $56.6M, Aligning with Consensus of $55.99M
select
2025-11-05
16:30:00
CVRx Announces Q3 EPS of 49c, Slightly Below Consensus of 50c
select
2025-08-04 (ET)
2025-08-04
16:29:48
CVRx appoints Brent Binkowski as COO
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
11-06NASDAQ.COM
Medtech Stocks Surge in After-Hours Trading: RxSight, Penumbra, and Evolus Take the Lead

  • RxSight's After-Hours Surge: RxSight shares jumped 18.1% after reporting a wider net loss and a 14% revenue decline, but improved its full-year revenue guidance and gross margin outlook.

  • Penumbra's Strong Performance: Penumbra's stock rose 16.4% following a strong Q3 with increased net income and revenue, along with a raised full-year revenue forecast.

  • Evolus Continues Gains: Evolus saw a 13.5% increase in after-hours trading after narrowing its net loss and reporting revenue growth, while reaffirming its full-year revenue guidance.

  • Modest Growth for Other Companies: CVRx and Cytek Biosciences also experienced after-hours gains, with CVRx reporting a slight improvement in losses and revenue growth, while Cytek reaffirmed its future revenue guidance despite a net loss.

[object Object]
Preview
7.0
07-16Newsfilter
CVRx Announces Positive News on Outpatient Payment for Barostim

  • CMS Proposal for Barostim: CVRx, Inc. announced that the Centers for Medicare and Medicaid Services (CMS) proposed to maintain the Barostim implant procedure under the New Technology Ambulatory Payment Classification with a payment of approximately $45,000, while also seeking comments on a potential Level 6 Neurostimulator APC.

  • Reimbursement Developments: Recent updates indicate that Barostim will transition to higher reimbursement categories, including a higher paying MS-DRG for inpatient procedures and moving from Category III to Category I CPT codes for physician payments, enhancing access for heart failure patients.

[object Object]
Preview
1.0
05-29Newsfilter
CVRx to Present at the William Blair 45th Annual Growth Stock Conference

  • Company Presentation Announcement: CVRx, Inc. will present at the William Blair 45th Annual Growth Stock Conference on June 4, 2025, at 10:00am Central Time, with a live audio webcast available on their investor relations page.

  • About CVRx and Barostim: CVRx specializes in neuromodulation solutions for cardiovascular diseases, notably the FDA-approved Barostim device, which helps alleviate heart failure symptoms by restoring balance to the autonomic nervous system.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is CVRx Inc (CVRX) stock price today?

The current price of CVRX is 9.35 USD — it has increased 0.97 % in the last trading day.

arrow icon

What is CVRx Inc (CVRX)'s business?

CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programmed by a wireless clinician-controlled programmer that communicates with the IPG.

arrow icon

What is the price predicton of CVRX Stock?

Wall Street analysts forecast CVRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVRX is 12.67 USD with a low forecast of 11.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is CVRx Inc (CVRX)'s revenue for the last quarter?

CVRx Inc revenue for the last quarter amounts to 14.69M USD, increased 9.85 % YoY.

arrow icon

What is CVRx Inc (CVRX)'s earnings per share (EPS) for the last quarter?

CVRx Inc. EPS for the last quarter amounts to -0.49 USD, decreased -14.04 % YoY.

arrow icon

What changes have occurred in the market's expectations for CVRx Inc (CVRX)'s fundamentals?

The market is revising Upward the revenue expectations for CVRx, Inc. (CVRX) for FY2025, with the revenue forecasts being adjusted by 0.26% over the past three months. During the same period, the stock price has changed by 19.57%.
arrow icon

How many employees does CVRx Inc (CVRX). have?

CVRx Inc (CVRX) has 206 emplpoyees as of December 05 2025.

arrow icon

What is CVRx Inc (CVRX) market cap?

Today CVRX has the market capitalization of 245.06M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free